Welcome to our dedicated page for Inozyme Pharma news (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.
Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at treating rare metabolic diseases. Focusing on disorders linked to paradoxical mineralization, Inozyme is pioneering solutions for conditions impacting vasculature, soft tissue, and skeletal health. Their lead drug, INZ-701, is an enzyme replacement therapy designed to correct defects in pathways involving ENPP1 and ABCC6 deficiencies.
INZ-701 showcases promise in treating diseases such as pseudoxanthoma elasticum (PXE) and generalized arterial calcification of infancy (GACI). This drug, currently in Phase 1/2 clinical trials, has demonstrated positive preliminary results, including safety, pharmacokinetic, and pharmacodynamic data, as well as trends toward clinical improvement. The trials indicate that INZ-701 increases plasma pyrophosphate (PPi) levels, a crucial marker for these conditions.
During the trials, INZ-701 was generally well tolerated with favorable safety profiles. Inozyme has undertaken comprehensive natural history studies to better understand the progression of ABCC6 Deficiency, especially in pediatric populations at high risk for severe complications like strokes.
In addition to their clinical advancements, Inozyme is committed to expanding its pipeline and therapeutic focus, planning pivotal trials for both pediatric and adult populations affected by these genetic disorders. The company also actively engages with patient communities and global health institutions to further research and raise awareness.
For real-time updates and detailed information, visit Inozyme Pharma or follow them on LinkedIn, X (formerly Twitter), and Facebook.
Inozyme Pharma (Nasdaq: INZY) announced that Yves Sabbagh, Ph.D., will present preliminary data from the ongoing Phase 1/2 clinical trial of INZ-701 in patients with ENPP1 Deficiency at the European Calcified Tissue Society Congress on April 17, 2023. The trial has shown positive preliminary pharmacokinetic, pharmacodynamic, and safety data, with ongoing dosing in the Phase 2 portion. The company plans to report interim data in Q3 2023 and add a new cohort for once-weekly dosing investigation.
ENPP1 Deficiency is a serious condition leading to high morbidity in infants and lacks approved therapies. The trial assesses INZ-701's safety and PK/PD profile, with exploratory endpoints focusing on calcification and functional outcomes.
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases, announced that Douglas A. Treco, Ph.D., CEO and Chairman, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, from 9:30 to 10:10 AM ET.
A live webcast of this event will be available on the Investor Relations section of Inozyme's website, along with a replay for a limited time.
Inozyme is developing INZ-701, an enzyme replacement therapy targeting pathologic mineralization and intimal proliferation associated with severe diseases. Currently, INZ-701 is in Phase 1/2 clinical trials for ENPP1 Deficiency and ABCC6 Deficiency.
Inozyme Pharma (Nasdaq: INZY) announced the grant of an inducement award to its newly appointed Chief Operations Officer, Matthew Winton, Ph.D., effective April 3, 2023. The award includes a nonstatutory option to purchase up to 250,000 shares at an exercise price of $5.39 per share, corresponding to the company's closing share price on the grant date. The option has a 10-year term and vests over four years. Inozyme Pharma specializes in developing therapeutics for rare diseases, including therapies like INZ-701 for pathologic mineralization, currently in Phase 1/2 clinical trials.
Inozyme Pharma (Nasdaq: INZY) announced the retirement of founding CEO Axel Bolte, effective April 1, 2023, with Douglas A. Treco, Ph.D. set to succeed him. Matthew Winton, Ph.D. has been appointed COO. Recent financial results for the year ending December 31, 2022, show a net loss of $67.1 million, or $1.78 per share. However, the company maintains a strong cash position of $127.9 million and expects to fund operations into Q4 2024. Ongoing clinical trials for INZ-701 show positive topline data, and the company is on track for pivotal trial initiation later this year.
FAQ
What is the current stock price of Inozyme Pharma (INZY)?
What is the market cap of Inozyme Pharma (INZY)?
What does Inozyme Pharma specialize in?
What is INZ-701?
What conditions is INZ-701 intended to treat?
What are the latest clinical trial results for INZ-701?
What are ENPP1 and ABCC6 Deficiencies?
Does Inozyme Pharma have any ongoing clinical trials?
What is the significance of plasma pyrophosphate (PPi) levels?
What partnerships does Inozyme Pharma have?
How can I stay updated on Inozyme Pharma's progress?
What are Inozyme Pharma's future plans?
